Background: The muscular dystrophies comprise a heterogeneous group of disorders characterized by the absence of specific glycoproteins located at or near the cell membrane. The effects of dystrophin deficiency on diaphragm contractile function are well delineated, whereas the consequences of merosin (laminin α2) deficiency are not well defined. Objectives: Studies tested the hypothesis that genetic deficiency of merosin alters diaphragm fatigue resistance. Methods: Diaphragm contractile performance was tested in vitro using dy/dy dystrophic mice, which have the same biochemical defect as human classic congenital muscular dystrophies. Results: Twitch force/area was reduced by 46% in dy/dy dystrophic diaphragm, but isometric twitch kinetics were not altered. During repetitive 25-Hz stimulation, normal muscle demonstrated early force potentiation lasting 20 s. This was followed by a fast decline in force, with total force loss of ∼45% over 2 min. Force of dystrophic diaphragm also increased at the onset of stimulation, but remained elevated over baseline values for up to 70 s. Force decline thereafter was slow, amounting to ∼5% after 2 min and (in a subset of muscle samples stimulated for longer durations) ∼20% after 5 min. Relaxation rate of normal muscle slowed considerably during repetitive stimulation, whereas that of dy/dy dystrophic diaphragm remained constant. Conclusions: Merosin deficiency increases diaphragm force potentiation and reduces fatigue despite considerable muscle weakness. We speculate that the former may be important for maintaining ventilatory homeostasis in the merosin-deficient muscular dystrophies.

Keywords:
Muscle, Contraction, Fatigue, Diaphragm, Muscular dystrophy, Laminin, Merosin
1.
Cohn RD, Campbell KP: Molecular basis of muscular dystrophies. Muscle Nerve 2000;23:1456–1471.
2.
Dangain J, Neering I: Mouse models of muscular dystrophy: gene products and function. News Physiol Sci 1992;7:195–199.
3.
Emery AEH: The muscular dystrophies. Lancet 2002;359:687–695.
4.
Worton R: Muscular dystrophies: Diseases of the dystrophin-glycoprotein complex. Science 1995;270:755–756.
5.
Bulfield G, Siller WG, Wight PA, Moore KJ: X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984;81:1189–1192.
6.
Sicinski P, Geng Y, Ryder-Cook AS, Bernard EA, Darlison MG, Barnard PJ: The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 1989;244:1578–1580.
7.
Michelson AM, Russell ES, Harman PJ: Dystrophia muscularis: A hereditary primary myopathy in the house mouse. Proc Natl Acad Sci USA 1955;41:1079–1084.
8.
Xu H, Christmas P, Wu XR, Wewer UM, Engvall E: Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse. Proc Natl Acad Sci USA 1994;91:5572–5576.
9.
Xu H, Wu XR, Wewer UM, Engvall E: Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet 1994;8:297–302.
10.
Dupont-Versteegden EE, McCarter RJ: Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of MDX mice. Muscle Nerve 1992;15:1105–1110.
11.
Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM: The MDX mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991;342:536–538.
12.
Connolly AM, Keeling RM, Mehta S, Pestronk A, Sanes JR: Three mouse models of muscular dystrophy: The natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice. Neuromusc Disord 2001;11:703–712.
13.
Hayes A, Williams DA: Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse. I. Clenbuterol. J Neurol Sci 1998;157:122–128.
14.
Yang L, Luo J, Petrof BJ: Corticosteroid therapy does not alter the threshold for contraction induced injury in dystrophic (mdx) mouse diaphragm. Muscle Nerve 1998;21:394–397.
15.
van Lunteren E, Manubay P: Inotropic effects of the K+ channel blocker TEA on dystrophic (mdx and dy/dy) mouse diaphragm. Respir Physiol 2001;125:249–254.
16.
van Lunteren E, Moyer M: Improvement of dy/dy dystrophic diaphragm by 3,4-diaminopyridine. Muscle Nerve 2002;26:71–78.
17.
van Lunteren E, Moyer M: Effects of DAP on diaphragm force and fatigue, including fatigue due to neurotransmission failure. J Appl Physiol 1996;81:2214–2220.
18.
Wineinger MA, Walsh SA, Abresch RT: The effect of age and tempature on mdx muscle fatigue. Muscle Nerve 1998;21:1075–1077.
19.
Moens P, Baatsen PHWW, Marechal G: Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 1993;14:446–451.
20.
Quinlan JG, Johnson SR, McKee MK, Lyden SP: Twitch and tetanus in mdx mouse muscle. Muscle Nerve 1992;15:837–842.
21.
Esau SA, Sperelakis N: Effect of low chloride on relaxation in hamster diaphragm muscle. J Appl Physiol 1986;61:180–184.
22.
Verburg E, Thorud HM, Eriksen M, Vollestad NK, Sejersted OM: Muscle contractile properties during intermittent nontetanic stimulation in rat skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2001;281:R1952–R1965.
23.
Gordon DA, Enoka RN, Stuart DG: Motor-unit force potentiation in adult cats during a standard fatigue test. J Physiol 1990;421:569–582.
24.
van Lunteren E, Vafaie H: Force potentiation in respiratory muscles: Comparison of diaphragm and sternohyoid. Am J Physiol 1993;264:R1095–R1100.
25.
Williams JH: Depression of posttetanic twitch potentiation by low calcium and calcium channel antagonists. J Appl Physiol 1990;69:1093–1097.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.